Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

M. S. Zabriskie, C. A. Eide, D. Yan, N. A. Vellore, A. D. Pomicter, S. L. Savage, B. J. Druker, M. W. Deininger, T. O'Hare

Research output: Contribution to journal › Letter › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia'. Together they form a unique fingerprint.